5.39 USD
+0.01 (+0.19%)
We assign a fundamental rating of 2 out of 10 to IMMX. IMMX was compared to 525 industry peers in the Biotechnology industry. While IMMX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, IMMX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year IMMX has reported negative net income.
- In the past year IMMX has reported a negative cash flow from operations.
- IMMX had negative earnings in each of the past 5 years.
- IMMX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -117.34%, IMMX is not doing good in the industry: 78.48% of the companies in the same industry are doing better.
- Looking at the Return On Equity, with a value of -285.09%, IMMX is doing worse than 72.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -117.34% | ||
| ROE | -285.09% | ||
| ROIC | N/A |
ROA(3y)-75.6%
ROA(5y)-114.76%
ROE(3y)-106.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- IMMX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for IMMX has been increased compared to 1 year ago.
- IMMX has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for IMMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -0.97, we must say that IMMX is in the distress zone and has some risk of bankruptcy.
- IMMX has a Altman-Z score of -0.97. This is comparable to the rest of the industry: IMMX outperforms 55.62% of its industry peers.
- There is no outstanding debt for IMMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.97 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- IMMX has a Current Ratio of 1.53. This is a normal value and indicates that IMMX is financially healthy and should not expect problems in meeting its short term obligations.
- IMMX's Current ratio of 1.53 is on the low side compared to the rest of the industry. IMMX is outperformed by 80.76% of its industry peers.
- A Quick Ratio of 1.53 indicates that IMMX should not have too much problems paying its short term obligations.
- The Quick ratio of IMMX (1.53) is worse than 79.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.53 | ||
| Quick Ratio | 1.53 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 9.31% over the past year.
EPS 1Y (TTM)9.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 48.14% on average over the next years. This is a very strong growth
- Based on estimates for the next years, IMMX will show a very strong growth in Revenue. The Revenue will grow by 155.56% on average per year.
EPS Next Y12.6%
EPS Next 2Y16.75%
EPS Next 3Y46.2%
EPS Next 5Y48.14%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y223.96%
Revenue Next 5Y155.56%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for IMMX. In the last year negative earnings were reported.
- Also next year IMMX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as IMMX's earnings are expected to grow with 46.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.75%
EPS Next 3Y46.2%
5. Dividend
5.1 Amount
- IMMX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IMMIX BIOPHARMA INC / IMMX FAQ
What is the fundamental rating for IMMX stock?
ChartMill assigns a fundamental rating of 2 / 10 to IMMX.
What is the valuation status of IMMIX BIOPHARMA INC (IMMX) stock?
ChartMill assigns a valuation rating of 1 / 10 to IMMIX BIOPHARMA INC (IMMX). This can be considered as Overvalued.
How profitable is IMMIX BIOPHARMA INC (IMMX) stock?
IMMIX BIOPHARMA INC (IMMX) has a profitability rating of 0 / 10.